<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><front><journal-meta><journal-id journal-id-type="nlm-ta">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="iso-abbrev">Evid Based Complement Alternat Med</journal-id><journal-id journal-id-type="publisher-id">ECAM</journal-id><journal-id journal-id-type="hwp">ecam</journal-id><journal-title-group><journal-title>Evidence-based Complementary and Alternative Medicine : eCAM</journal-title></journal-title-group><issn pub-type="ppub">1741-427X</issn><issn pub-type="epub">1741-4288</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18990724</article-id><article-id pub-id-type="pmc">3136370</article-id><article-id pub-id-type="doi">10.1093/ecam/nen069</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Dietary Soy Supplement on Fibromyalgia Symptoms: A Randomized, Double-Blind, Placebo-Controlled, Early Phase Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wahner-Roedler</surname><given-names>Dietlind L.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Thompson</surname><given-names>Jeffrey M.</given-names></name><xref ref-type="aff" rid="I2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Luedtke</surname><given-names>Connie A.</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>King</surname><given-names>Susan M.</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cha</surname><given-names>Stephen S.</given-names></name><xref ref-type="aff" rid="I4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Elkin</surname><given-names>Peter L.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bruce</surname><given-names>Barbara K.</given-names></name><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Townsend</surname><given-names>Cynthia O.</given-names></name><xref ref-type="aff" rid="I5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bergeson</surname><given-names>Jody R.</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Eickhoff</surname><given-names>Andrea L.</given-names></name><xref ref-type="aff" rid="I3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Loehrer</surname><given-names>Laura L.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sood</surname><given-names>Amit</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bauer</surname><given-names>Brent A.</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Division of General Internal Medicine, Mayo Clinic, Rochester, MN, USA</aff><aff id="I2"><sup>2</sup>The Fibromyalgia Treatment Program, Mayo Clinic, Rochester, MN, USA</aff><aff id="I3"><sup>3</sup>The Fibromyalgia Treatment/Rehabilitation Center, Mayo Clinic, Rochester, MN, USA</aff><aff id="I4"><sup>4</sup>The Division of Biostatistics, Mayo Clinic, Rochester, MN, USA</aff><aff id="I5"><sup>5</sup>The Division of Tertiary Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA</aff><author-notes><corresp id="cor1">*Dietlind L. Wahner-Roedler: <email>wahnerroedler.dietlind@mayo.edu</email></corresp></author-notes><pub-date pub-type="ppub"><year>2011</year></pub-date><pub-date pub-type="epub"><day>23</day><month>6</month><year>2011</year></pub-date><volume>2011</volume><elocation-id>350697</elocation-id><history><date date-type="received"><day>25</day><month>11</month><year>2008</year></date><date date-type="accepted"><day>28</day><month>5</month><year>2009</year></date></history><permissions><copyright-statement>Copyright © 2011 Dietlind L. Wahner-Roedler et al.</copyright-statement><copyright-year>2011</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p><offsets xml_i="4956" xml_f="5831" txt_i="11" txt_f="886">Most patients with fibromyalgia use complementary and alternative medicine (CAM). Properly designed controlled trials are necessary to assess the effectiveness of these practices. This study was a randomized, double-blind, placebo-controlled, early phase trial. Fifty patients seen at a fibromyalgia outpatient treatment program were randomly assigned to a daily soy or placebo (casein) shake. Outcome measures were scores of the Fibromyalgia Impact Questionnaire (FIQ) and the Center for Epidemiologic Studies Depression Scale (CES-D) at baseline and after 6 weeks of intervention. Analysis was with standard statistics based on the null hypothesis, and separation test for early phase CAM comparative trials. Twenty-eight patients completed the study. Use of standard statistics with intent-to-treat analysis showed that total FIQ scores decreased by 14% in the soy group (</offsets><italic><offsets xml_i="5839" xml_f="5840" txt_i="886" txt_f="887">P</offsets></italic><offsets xml_i="5849" xml_f="5890" txt_i="887" txt_f="928"> = .02) and by 18% in the placebo group (</offsets><italic><offsets xml_i="5898" xml_f="5899" txt_i="928" txt_f="929">P</offsets></italic><offsets xml_i="5908" xml_f="5996" txt_i="929" txt_f="1014"> &lt; .001). The difference in change in scores between the groups was not significant (</offsets><italic><offsets xml_i="6004" xml_f="6005" txt_i="1014" txt_f="1015">P</offsets></italic><offsets xml_i="6014" xml_f="6095" txt_i="1015" txt_f="1096"> = .16). With the same analysis, CES-D scores decreased in the soy group by 16% (</offsets><italic><offsets xml_i="6103" xml_f="6104" txt_i="1096" txt_f="1097">P</offsets></italic><offsets xml_i="6113" xml_f="6155" txt_i="1097" txt_f="1139"> = .004) and in the placebo group by 15% (</offsets><italic><offsets xml_i="6163" xml_f="6164" txt_i="1139" txt_f="1140">P</offsets></italic><offsets xml_i="6173" xml_f="6230" txt_i="1140" txt_f="1197"> = .05). The change in scores was similar in the groups (</offsets><italic><offsets xml_i="6238" xml_f="6239" txt_i="1197" txt_f="1198">P</offsets></italic><offsets xml_i="6248" xml_f="6764" txt_i="1198" txt_f="1714"> = .83). Results of statistical analysis using the separation test and intent-to-treat analysis revealed no benefit of soy compared with placebo. Shakes that contain soy and shakes that contain casein, when combined with a multidisciplinary fibromyalgia treatment program, provide a decrease in fibromyalgia symptoms. Separation between the effects of soy and casein (control) shakes did not favor the intervention. Therefore, large-sample studies using soy for patients with fibromyalgia are probably not indicated.</offsets></p></abstract></article-meta></front><body><sec id="sec1"><title><offsets xml_i="6830" xml_f="6845" txt_i="1722" txt_f="1737">1. Introduction</offsets></title><p><offsets xml_i="6856" xml_f="6965" txt_i="1738" txt_f="1847">Fibromyalgia syndrome (FMS) is a chronic, generalized pain syndrome that affects the musculoskeletal system [</offsets><xref rid="B1" ref-type="bibr"><offsets xml_i="6996" xml_f="6997" txt_i="1847" txt_f="1848">1</offsets></xref><offsets xml_i="7004" xml_f="7172" txt_i="1848" txt_f="2016">]. This syndrome is typically diagnosed in patients who experience generalized musculoskeletal pain and have excessive tenderness in at least 11 of 18 specific points [</offsets><xref rid="B2" ref-type="bibr"><offsets xml_i="7203" xml_f="7204" txt_i="2016" txt_f="2017">2</offsets></xref><offsets xml_i="7211" xml_f="7657" txt_i="2017" txt_f="2463">]. Although the primary cause of FMS is unclear, a growing body of evidence indicates that the widespread pain associated with this syndrome is due to abnormalities in the central nervous system. Therefore, drug therapy for FMS is most often aimed at the central nervous system and includes tricyclic antidepressants, selective serotonin reuptake inhibitors, dual serotonin and norepinephrine reuptake inhibitors, analgesics and anticonvulsants [</offsets><xref rid="B1" ref-type="bibr"><offsets xml_i="7688" xml_f="7689" txt_i="2463" txt_f="2464">1</offsets></xref><offsets xml_i="7696" xml_f="7698" txt_i="2464" txt_f="2466">].</offsets></p><p><offsets xml_i="7705" xml_f="7832" txt_i="2467" txt_f="2594">In addition to medical therapies, complementary and alternative medicine (CAM) therapies have been used to treat FMS symptoms [</offsets><xref rid="B3" ref-type="bibr"><offsets xml_i="7863" xml_f="7864" txt_i="2594" txt_f="2595">3</offsets></xref><offsets xml_i="7871" xml_f="7968" txt_i="2595" txt_f="2689">]. Overall, &gt;50% of patients with rheumatologic conditions, including FMS, use CAM therapies [</offsets><xref rid="B4" ref-type="bibr"><offsets xml_i="7999" xml_f="8000" txt_i="2689" txt_f="2690">4</offsets></xref><offsets xml_i="8007" xml_f="8008" txt_i="2690" txt_f="2691">–</offsets><xref rid="B6" ref-type="bibr"><offsets xml_i="8039" xml_f="8040" txt_i="2691" txt_f="2692">6</offsets></xref><offsets xml_i="8047" xml_f="8073" txt_i="2692" txt_f="2718">]. Wahner-Roedler et al. [</offsets><xref rid="B6" ref-type="bibr"><offsets xml_i="8104" xml_f="8105" txt_i="2718" txt_f="2719">6</offsets></xref><offsets xml_i="8112" xml_f="8534" txt_i="2719" txt_f="3141">] reported that 98% of patients who are referred to a fibromyalgia treatment program may have used some form of CAM within the last 6 months. The types of CAM therapies used to reduce FMS symptoms include massage, meditation, acupuncture, hypnotherapy and dietary supplementation. Few CAM interventions have been adequately tested in controlled clinical trials. In a systematic review published in 2003, Holdcraft et al. [</offsets><xref rid="B3" ref-type="bibr"><offsets xml_i="8565" xml_f="8566" txt_i="3141" txt_f="3142">3</offsets></xref><offsets xml_i="8573" xml_f="8672" txt_i="3142" txt_f="3241">] concluded that the strongest evidence for efficacy in FMS exists for acupuncture. Magnesium use, </offsets><italic><offsets xml_i="8680" xml_f="8681" txt_i="3241" txt_f="3242">S</offsets></italic><offsets xml_i="8690" xml_f="8972" txt_i="3242" txt_f="3524">-adenosyl-L-methionine (SAMe) use, and massage therapy have moderate evidence; chlorella use, relaxation, biofeedback, magnet therapies, homeopathy, botanical oils, balneotherapy and use of anthocyanidins have limited evidence. In a 2004 published summary of CAM trial data, Ernst [</offsets><xref rid="B7" ref-type="bibr"><offsets xml_i="9003" xml_f="9004" txt_i="3524" txt_f="3525">7</offsets></xref><offsets xml_i="9011" xml_f="9214" txt_i="3525" txt_f="3728">] concluded that acupuncture and spinal manipulations have shown a significant promise in the treatment of FMS. No dietary supplement has conclusive evidence of efficacy in the treatment of FMS symptoms.</offsets></p><p><offsets xml_i="9221" xml_f="9405" txt_i="3729" txt_f="3913">Soy is a widely used dietary supplement that has not been previously tested for treating FMS. On the basis of studies indicating that dietary soy relieves neuropathic pain in animals [</offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="9436" xml_f="9437" txt_i="3913" txt_f="3914">8</offsets></xref><offsets xml_i="9444" xml_f="9445" txt_i="3914" txt_f="3915">–</offsets><xref rid="B11" ref-type="bibr"><offsets xml_i="9477" xml_f="9479" txt_i="3915" txt_f="3917">11</offsets></xref><offsets xml_i="9486" xml_f="9584" txt_i="3917" txt_f="4015">] and reduces pain and improves range of motion of the knee joints in humans with osteoarthritis [</offsets><xref rid="B12" ref-type="bibr"><offsets xml_i="9616" xml_f="9618" txt_i="4015" txt_f="4017">12</offsets></xref><offsets xml_i="9625" xml_f="10005" txt_i="4017" txt_f="4397">], we hypothesized that soy consumption might improve FMS symptoms. The aim of our study was to evaluate whether dietary soy supplement can improve symptoms in patients with FMS participating in a 1.5-day multidisciplinary fibromyalgia treatment program, as measured by the Fibromyalgia Impact Questionnaire (FIQ) and the Center for Epidemiologic Studies Depression Scale (CES-D).</offsets></p></sec><sec id="sec2"><title><offsets xml_i="10037" xml_f="10060" txt_i="4399" txt_f="4422">2. Subjects and Methods</offsets></title><p><offsets xml_i="10071" xml_f="10194" txt_i="4423" txt_f="4546">This study was approved by the Mayo Clinic Institutional Review Board and registered as NCT00279942 in Clinical Trials.gov.</offsets></p><p><offsets xml_i="10201" xml_f="10768" txt_i="4547" txt_f="5114">Patients presenting to the Mayo Fibromyalgia Treatment Program between May 2006 and August 2006 were invited to participate in this trial. Exclusion criteria included diagnoses of bipolar disorder, schizophrenia, dementia, diabetes mellitus and inflammatory bowel disease; allergy to soy or other study product ingredients; pregnancy; and consumption of soy products within the past 30 days. Among patients seen in our Fibromyalgia Treatment Program between May 2006 and August 2006, 117 met the study inclusion criteria and were invited to participate in the study (</offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="10800" xml_f="10808" txt_i="5114" txt_f="5122">Figure 1</offsets></xref><offsets xml_i="10815" xml_f="10956" txt_i="5122" txt_f="5263">). Of these, 67 patients declined to participate, and the remaining 50 patients were randomly assigned to either soy supplement or placebo. 
</offsets></p><sec sec-type="subsection" id="sec2.1"><title><offsets xml_i="11006" xml_f="11050" txt_i="5264" txt_f="5308">2.1. The Mayo Fibromyalgia Treatment Program</offsets></title><p><offsets xml_i="11061" xml_f="11824" txt_i="5309" txt_f="6072">The Mayo Fibromyalgia Treatment Program is a 1.5 day, multidisciplinary outpatient program staffed by physicians from the Department of Physical Medicine and Rehabilitation and the Department of Rheumatology. Access to this program is limited to patients with a presumed diagnosis of FMS who are referred by Mayo Clinic physicians. The patients undergo an initial evaluation by a registered nurse specifically trained in rheumatologic disorders, with the collaboration of a physician to confirm the diagnosis. Only patients with a confirmed diagnosis of FMS as defined by the American College of Rheumatology in 1990—namely, widespread musculoskeletal pain of at least 3 months' duration and excessive tenderness in at least 11 of 18 predefined anatomical sites [</offsets><xref rid="B2" ref-type="bibr"><offsets xml_i="11855" xml_f="11856" txt_i="6072" txt_f="6073">2</offsets></xref><offsets xml_i="11863" xml_f="12367" txt_i="6073" txt_f="6577">]—are enrolled in the program. Components of the program are carried out by a core group of team members that includes registered nurses, rheumatologists, psychiatrists, occupational therapists, physical therapists and ancillary staff. The mission of the fibromyalgia treatment program is to improve patients' physical and mental health functioning, impart evidence-based information and create a standardized treatment approach. Further details about this multidisciplinary program have been described [</offsets><xref rid="B13" ref-type="bibr"><offsets xml_i="12399" xml_f="12401" txt_i="6577" txt_f="6579">13</offsets></xref><offsets xml_i="12408" xml_f="12410" txt_i="6579" txt_f="6581">].</offsets></p></sec><sec sec-type="subsection" id="sec2.2"><title><offsets xml_i="12466" xml_f="12483" txt_i="6583" txt_f="6600">2.2. Study Design</offsets></title><p><offsets xml_i="12494" xml_f="13279" txt_i="6601" txt_f="7386">We conducted a randomized, double-blind, placebo-controlled, early phase trial. Participants were randomly assigned to either soy supplement or placebo when they started the fibromyalgia treatment program. An informed consent was obtained from all participants. The participants completed the FIQ and the CES-D at baseline and were randomly assigned to either soy supplement or placebo taken once a day for 6 weeks. They were asked to collect wrappers of the product and to send them by mail in a provided envelope addressed to Mayo Clinic, together with another set of the completed FIQ and CES-D forms, at the end of the 6 weeks. The study coordinator, for whom the assignment of patients was blinded, called the participants weekly to inquire about product tolerance and compliance.</offsets></p></sec><sec sec-type="subsection" id="sec2.3"><title><offsets xml_i="13335" xml_f="13348" txt_i="7388" txt_f="7401">2.3. Products</offsets></title><p><offsets xml_i="13359" xml_f="13742" txt_i="7402" txt_f="7785">The treatment was a soy shake (provided by Physicians Pharmaceuticals, Inc, Kernersville, NC, USA) that contained 20 g of soy protein and 160 mg of soy isoflavone. The placebo was a shake that contained 20 g of milk-based protein (casein) and no isoflavone (provided by Physicians Pharmaceuticals, Inc). Flavoring, sweetening and nutritional content were identical in the two shakes.</offsets></p></sec><sec sec-type="subsection" id="sec2.4"><title><offsets xml_i="13798" xml_f="13814" txt_i="7787" txt_f="7803">2.4. Instruments</offsets></title><sec sec-type="subsubsection" id="sec2.4.1"><title><offsets xml_i="13873" xml_f="13913" txt_i="7804" txt_f="7844">2.4.1. Fibromyalgia Impact Questionnaire</offsets></title><p><offsets xml_i="13924" xml_f="14041" txt_i="7845" txt_f="7962">The FIQ is a validated questionnaire that was developed to measure status, progress and outcomes of people with FMS [</offsets><xref rid="B14" ref-type="bibr"><offsets xml_i="14073" xml_f="14075" txt_i="7962" txt_f="7964">14</offsets></xref><offsets xml_i="14082" xml_f="14126" txt_i="7964" txt_f="8008">]. A self-administered instrument, it takes </offsets><italic><offsets xml_i="14134" xml_f="14135" txt_i="8008" txt_f="8009">∼</offsets></italic><offsets xml_i="14144" xml_f="14514" txt_i="8009" txt_f="8379">5 min to complete. The FIQ contains 20 items that measure physical functioning; symptoms of pain, fatigue, morning tiredness and stiffness; job difficulty; depression and anxiety; days of work missed; and overall well-being of the person during the previous week. A higher score indicates a greater effect of FMS on the person, with a range of total score from 0 to 100.</offsets></p><p><offsets xml_i="14521" xml_f="15199" txt_i="8380" txt_f="9058">Questions 1 through 11 rate the ability to complete various activities and are scored and summed to yield 1 physical impairment score (0, no impairment; 10, maximum impairment). Question 12 inquires about the number of days out of the past 7 when the patient felt good, and question 13 inquires about the number of days during the past week when the patient missed work, including housework, because of fibromyalgia, with each question yielding a separate score (0, no impairment; 10, maximum impairment). Questions 14 through 20 are a series of visual analog scales (range, 0–10) for rating the various symptoms characteristic of FMS (0, no impairment; 70, maximum impairment).</offsets></p></sec><sec sec-type="subsubsection" id="sec2.4.2"><title><offsets xml_i="15260" xml_f="15316" txt_i="9060" txt_f="9116">2.4.2. Center for Epidemiologic Studies Depression Scale</offsets></title><p><offsets xml_i="15327" xml_f="15543" txt_i="9117" txt_f="9333">The CES-D is a 20-item measure of depression. Its questions represent depressed mood; feelings of guilt, worthlessness, helplessness or hopelessness; psychomotor retardation; loss of appetite; and sleep disturbance [</offsets><xref rid="B15" ref-type="bibr"><offsets xml_i="15575" xml_f="15577" txt_i="9333" txt_f="9335">15</offsets></xref><offsets xml_i="15584" xml_f="15753" txt_i="9335" txt_f="9504">]. Scale scores can range from 0 to 60; a higher number indicates greater depression. Various cutoff points for depression have been used. For example, Weissman et al. [</offsets><xref rid="B16" ref-type="bibr"><offsets xml_i="15785" xml_f="15787" txt_i="9504" txt_f="9506">16</offsets></xref><offsets xml_i="15794" xml_f="15835" txt_i="9506" txt_f="9547">] used the cutoff of 16 and Turk et al. [</offsets><xref rid="B17" ref-type="bibr"><offsets xml_i="15867" xml_f="15869" txt_i="9547" txt_f="9549">17</offsets></xref><offsets xml_i="15876" xml_f="15895" txt_i="9549" txt_f="9568">] the cutoff of 19.</offsets></p></sec></sec><sec sec-type="subsection" id="sec2.5"><title><offsets xml_i="15957" xml_f="15982" txt_i="9571" txt_f="9596">2.5. Statistical Analysis</offsets></title><p><offsets xml_i="15993" xml_f="16762" txt_i="9597" txt_f="10366">Patient demographics were summarized using descriptive statistics. The mean (±SD) of the total FIQ scores and the CES-D scores at baseline and at 6 weeks between the soy group and the placebo group were analyzed by Wilcoxon rank sum test. The difference and relative change (%) of the FIQ and CES-D scores at 6 weeks from baseline were also compared by Wilcoxon rank sum test. The comparison of the difference from baseline to 6 weeks within the soy and placebo groups was analyzed by the Wilcoxon signed rank test. The analyses were performed using intent-to-treat and per-protocol approaches. In intent-to-treat analysis, a participant who did not complete the entire 6-week supplement trial or who failed to complete the FIQ and CES-D forms was considered a dropout.</offsets></p><p><offsets xml_i="16769" xml_f="16919" txt_i="10367" txt_f="10517">Because this study was an early phase trial with a small sample size, we also analyzed our data by using the separation test, as described by Aickin [</offsets><xref rid="B18" ref-type="bibr"><offsets xml_i="16951" xml_f="16953" txt_i="10517" txt_f="10519">18</offsets></xref><offsets xml_i="16960" xml_f="16962" txt_i="10519" txt_f="10521">, </offsets><xref rid="B19" ref-type="bibr"><offsets xml_i="16994" xml_f="16996" txt_i="10521" txt_f="10523">19</offsets></xref><offsets xml_i="17003" xml_f="17562" txt_i="10523" txt_f="11082">], to assess whether it is worthwhile to pursue research on soy supplementation for patients with fibromyalgia. By use of this test, the standard deviation of the effect estimate (SDE) of the mean difference can be found. The value of Δ = 1.645* SDE is then calculated. If the mean difference exceeds Δ/2 (in the favorable direction), further research is recommended; if it decreases below −Δ/2 (in the unfavorable direction), further research is not recommended. Otherwise, the statement is made that there is not enough information to make a recommendation.</offsets></p></sec></sec><sec id="sec3"><title><offsets xml_i="17600" xml_f="17610" txt_i="11085" txt_f="11095">3. Results</offsets></title><sec sec-type="subsection" id="sec3.1"><title><offsets xml_i="17664" xml_f="17693" txt_i="11096" txt_f="11125">3.1. Baseline Characteristics</offsets></title><p><offsets xml_i="17704" xml_f="17861" txt_i="11126" txt_f="11283">A total of 50 patients (49 women) were recruited for this trial. Median age was 47.7 years (range, 18–76 years). There was no significant difference in age (</offsets><italic><offsets xml_i="17869" xml_f="17870" txt_i="11283" txt_f="11284">P</offsets></italic><offsets xml_i="17879" xml_f="17900" txt_i="11284" txt_f="11305"> = .99), FIQ scores (</offsets><italic><offsets xml_i="17908" xml_f="17909" txt_i="11305" txt_f="11306">P</offsets></italic><offsets xml_i="17918" xml_f="17943" txt_i="11306" txt_f="11331"> = .36) or CES-D scores (</offsets><italic><offsets xml_i="17951" xml_f="17952" txt_i="11331" txt_f="11332">P</offsets></italic><offsets xml_i="17961" xml_f="18070" txt_i="11332" txt_f="11441"> = .48) between the two groups. Twenty-eight patients (56%)—12 in the soy group and 16 in the placebo group (</offsets><italic><offsets xml_i="18078" xml_f="18079" txt_i="11441" txt_f="11442">P</offsets></italic><offsets xml_i="18088" xml_f="18170" txt_i="11442" txt_f="11524"> = .39)—completed the 6-week trial. Reasons for not completing it are depicted in </offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="18202" xml_f="18210" txt_i="11524" txt_f="11532">Figure 1</offsets></xref><offsets xml_i="18217" xml_f="18362" txt_i="11532" txt_f="11677">. Patients who did not finish the trial were significantly younger (median age, 39.8 years) than those who finished it (median age, 53.9 years) (</offsets><italic><offsets xml_i="18370" xml_f="18371" txt_i="11677" txt_f="11678">P</offsets></italic><offsets xml_i="18380" xml_f="18577" txt_i="11678" txt_f="11872"> &lt; .001). The median FIQ score was higher for patients who did not complete the trial (59.5) than for those who completed the study (54.8), but the difference was not statistically significant (</offsets><italic><offsets xml_i="18585" xml_f="18586" txt_i="11872" txt_f="11873">P</offsets></italic><offsets xml_i="18595" xml_f="18806" txt_i="11873" txt_f="12084"> = .12). The median CES-D score also was higher for patients who did not complete the trial (26.5) than for patients who completed the trial (14.0), but this also was not a statistically significant difference (</offsets><italic><offsets xml_i="18814" xml_f="18815" txt_i="12084" txt_f="12085">P</offsets></italic><offsets xml_i="18824" xml_f="18832" txt_i="12085" txt_f="12093"> = .14).</offsets></p></sec><sec sec-type="subsection" id="sec3.2"><title><offsets xml_i="18888" xml_f="18918" txt_i="12095" txt_f="12125">3.2. Between-Group Comparisons</offsets></title><p><offsets xml_i="18929" xml_f="19104" txt_i="12126" txt_f="12301">With intent-to-treat analysis, the total FIQ scores determined at study entry and at study completion decreased 14% (±29) in the soy group and 18% (±25) in the placebo group (</offsets><italic><offsets xml_i="19112" xml_f="19113" txt_i="12301" txt_f="12302">P</offsets></italic><offsets xml_i="19122" xml_f="19253" txt_i="12302" txt_f="12433"> = .16). With per-protocol analysis, the total FIQ scores decreased 29% (±36) in the soy group and 28% (±26) in the placebo group (</offsets><italic><offsets xml_i="19261" xml_f="19262" txt_i="12433" txt_f="12434">P</offsets></italic><offsets xml_i="19271" xml_f="19280" txt_i="12434" txt_f="12443"> = .93) (</offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="19312" xml_f="19320" txt_i="12443" txt_f="12451">Figure 2</offsets></xref><offsets xml_i="19327" xml_f="19581" txt_i="12451" txt_f="12705">). No statistically significant decrease between the soy group and the placebo group was observed for any of the FIQ subclass scores. With intent-to-treat analysis, the CES-D scores improved 16% (±26) in the soy group and 15% (±41) in the placebo group (</offsets><italic><offsets xml_i="19589" xml_f="19590" txt_i="12705" txt_f="12706">P</offsets></italic><offsets xml_i="19599" xml_f="19725" txt_i="12706" txt_f="12832"> = .83); with per-protocol analysis, the CES-D scores improved 33% (±30) in the soy group and 24% (±50) in the placebo group (</offsets><xref ref-type="fig" rid="fig3"><offsets xml_i="19757" xml_f="19765" txt_i="12832" txt_f="12840">Figure 3</offsets></xref><offsets xml_i="19772" xml_f="19851" txt_i="12840" txt_f="12919">). However, the decrease between the groups was not statistically significant (</offsets><italic><offsets xml_i="19859" xml_f="19860" txt_i="12919" txt_f="12920">P</offsets></italic><offsets xml_i="19869" xml_f="20319" txt_i="12920" txt_f="13370"> = .96). Using various cutoff points for depression (CES-D ≥ 16, CES-D ≥ 19 and CES-D ≥ 27) and intent-to-treat analysis, we found a depression rate of 52%, 48% and 28%, respectively, in the soy group and 52%, 48% and 32% in the control group at study entry. After 6 weeks, these percentages were 48%, 44% and 24% in the treatment group and 48%, 36% and 24% in the control group. There was no statistically significant difference between the groups (</offsets><italic><offsets xml_i="20327" xml_f="20328" txt_i="13370" txt_f="13371">P</offsets></italic><offsets xml_i="20337" xml_f="20870" txt_i="13371" txt_f="13904"> = 1.00). Determined by using per-protocol analysis for these three different CES-D scores, the percentages of patients with depression at study entry in the treatment group were 42%, 33% and 8% and in the control group were 38%, 38% and 19%. After 6 weeks, 33% of the treatment group had CES-D scores of 16 or greater, 25% had scores of 19 or greater and 0% had scores of 27 or greater. The percentages for the control group were 31%, 19% and 6%, respectively. There was no statistically significant difference between the groups. 
</offsets></p><p><offsets xml_i="20877" xml_f="21234" txt_i="13905" txt_f="14262">The separation test using the difference from baseline to 6 weeks showed no benefit for soy, as determined by FIQ scores and CES-D scores for both intent-to-treat and per-protocol analyses. We did not have enough information to make any recommendation for or against the use of soy using the separation test per-protocol analysis based on total FIQ scores (</offsets><xref ref-type="table" rid="tab1"><offsets xml_i="21268" xml_f="21275" txt_i="14262" txt_f="14269">Table 1</offsets></xref><offsets xml_i="21282" xml_f="21286" txt_i="14269" txt_f="14273">). 
</offsets></p></sec><sec sec-type="subsection" id="sec3.3"><title><offsets xml_i="21342" xml_f="21371" txt_i="14275" txt_f="14304">3.3. Within-Group Comparisons</offsets></title><p><offsets xml_i="21382" xml_f="21451" txt_i="14305" txt_f="14374">Significant, but modest, improvement in total FIQ scores (soy group, </offsets><italic><offsets xml_i="21459" xml_f="21460" txt_i="14374" txt_f="14375">P</offsets></italic><offsets xml_i="21469" xml_f="21492" txt_i="14375" txt_f="14398"> = .02; placebo group, </offsets><italic><offsets xml_i="21500" xml_f="21501" txt_i="14398" txt_f="14399">P</offsets></italic><offsets xml_i="21510" xml_f="21523" txt_i="14399" txt_f="14409"> &lt; .001) (</offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="21555" xml_f="21563" txt_i="14409" txt_f="14417">Figure 2</offsets></xref><offsets xml_i="21570" xml_f="21601" txt_i="14417" txt_f="14448">) and CES-D scores (soy group, </offsets><italic><offsets xml_i="21609" xml_f="21610" txt_i="14448" txt_f="14449">P</offsets></italic><offsets xml_i="21619" xml_f="21643" txt_i="14449" txt_f="14473"> = .004; placebo group, </offsets><italic><offsets xml_i="21651" xml_f="21652" txt_i="14473" txt_f="14474">P</offsets></italic><offsets xml_i="21661" xml_f="21670" txt_i="14474" txt_f="14483"> = .05) (</offsets><xref ref-type="fig" rid="fig3"><offsets xml_i="21702" xml_f="21710" txt_i="14483" txt_f="14491">Figure 3</offsets></xref><offsets xml_i="21717" xml_f="21968" txt_i="14491" txt_f="14742">) between study entry and study completion was seen in both groups. Using three different cutoff points for depression (CES-D ≥ 16, CES-D ≥ 19 and CES-D ≥ 27), we found no significant improvement using the McNemar test for the soy and control groups (</offsets><italic><offsets xml_i="21976" xml_f="21977" txt_i="14742" txt_f="14743">P</offsets></italic><offsets xml_i="21986" xml_f="21997" txt_i="14743" txt_f="14751"> &gt; .50).</offsets></p><sec sec-type="subsubsection" id="sec3.3.1"><title><offsets xml_i="22052" xml_f="22078" txt_i="14752" txt_f="14778">3.3.1. FIQ Subclass Scores</offsets></title><p><offsets xml_i="22089" xml_f="22450" txt_i="14779" txt_f="15140">The average score of answers to questions 1 through 11 showed no significant improvement from before treatment to after treatment in both groups, as did the average score of answers to questions 12 and 13. However, the average score of answers to questions 14 through 20 showed significant improvement from before treatment to after treatment in the soy group (</offsets><italic><offsets xml_i="22458" xml_f="22459" txt_i="15140" txt_f="15141">P</offsets></italic><offsets xml_i="22468" xml_f="22500" txt_i="15141" txt_f="15173"> = .004) and the placebo group (</offsets><italic><offsets xml_i="22508" xml_f="22509" txt_i="15173" txt_f="15174">P</offsets></italic><offsets xml_i="22518" xml_f="22527" txt_i="15174" txt_f="15183"> = .001).</offsets></p></sec></sec></sec><sec id="sec4"><title><offsets xml_i="22571" xml_f="22584" txt_i="15187" txt_f="15200">4. Discussion</offsets></title><p><offsets xml_i="22595" xml_f="22822" txt_i="15201" txt_f="15428">The present study shows that use of soy product and use of the chosen placebo for 6 weeks, when combined with an educational intervention, were both associated with modest improvement in symptoms of fibromyalgia and depression.</offsets></p><p><offsets xml_i="22829" xml_f="23273" txt_i="15429" txt_f="15873">Patients seen in the Mayo Fibromyalgia Treatment Program have moderate to severe symptoms, as demonstrated by the high total FIQ score of our sample at study entry (average score, 59.4 ± 13.3). A 1.5-day multidisciplinary treatment program, such as the program developed at our institution is considered standard care for these patients and has been shown to have a significant positive effect on the impact of illness among patients with FMS [</offsets><xref rid="B13" ref-type="bibr"><offsets xml_i="23305" xml_f="23307" txt_i="15873" txt_f="15875">13</offsets></xref><offsets xml_i="23314" xml_f="23657" txt_i="15875" txt_f="16218">]. Despite participation in such multidisciplinary treatment programs and use of many conventional medications (e.g., tricyclic antidepressants, selective serotonin reuptake inhibitors, dual serotonin and norepinephrine reuptake inhibitors, analgesics, anticonvulsants), most patients with FMS continue to have functionally limiting symptoms [</offsets><xref rid="B20" ref-type="bibr"><offsets xml_i="23689" xml_f="23691" txt_i="16218" txt_f="16220">20</offsets></xref><offsets xml_i="23698" xml_f="23700" txt_i="16220" txt_f="16222">].</offsets></p><p><offsets xml_i="23707" xml_f="23961" txt_i="16223" txt_f="16477">Soy consumption has been reported in the CAM literature to have many beneficial effects on bone health, the cardiovascular system and degenerative arthritis and has been shown in epidemiologic studies to be associated with lower risk of several cancers [</offsets><xref rid="B21" ref-type="bibr"><offsets xml_i="23993" xml_f="23995" txt_i="16477" txt_f="16479">21</offsets></xref><offsets xml_i="24002" xml_f="24144" txt_i="16479" txt_f="16621">]. Intrigued by animal studies indicating that dietary soy provided relief in neuropathic pain, we decided to perform this early phase trial [</offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="24175" xml_f="24176" txt_i="16621" txt_f="16622">8</offsets></xref><offsets xml_i="24183" xml_f="24184" txt_i="16622" txt_f="16623">–</offsets><xref rid="B11" ref-type="bibr"><offsets xml_i="24216" xml_f="24218" txt_i="16623" txt_f="16625">11</offsets></xref><offsets xml_i="24225" xml_f="24759" txt_i="16625" txt_f="17159">]. Using standard statistics based on the null hypothesis, we show that the use of dietary soy is no more helpful than the use of casein when each is combined with a brief multidisciplinary treatment program. Although we cannot exclude the high drop-out rate, a patient population with severe symptoms as a result of referral bias, and a lack of efficacy of the soy product as reasons for these findings, another possible cause is the small sample size of our study, which represents an early phase trial. In concordance with Aickin [</offsets><xref rid="B18" ref-type="bibr"><offsets xml_i="24791" xml_f="24793" txt_i="17159" txt_f="17161">18</offsets></xref><offsets xml_i="24800" xml_f="24802" txt_i="17161" txt_f="17163">, </offsets><xref rid="B19" ref-type="bibr"><offsets xml_i="24834" xml_f="24836" txt_i="17163" txt_f="17165">19</offsets></xref><offsets xml_i="24843" xml_f="25474" txt_i="17165" txt_f="17796">], we believe that early phase research in CAM is important because of its large influence on the subsequent expenditure of money and effort in CAM therapies. By analyzing our data with separation testing, we were unable to document any separation between soy use and casein use (control) through FIQ and CES-D scores in favor of soy when using intent-to-treat analysis, as well as per-protocol analysis. Our interpretation of these results is that further studies using large sample sizes of patients with fibromyalgia are unlikely to show a positive effect of soy supplement compared with placebo and therefore are not indicated.</offsets></p><p><offsets xml_i="25481" xml_f="25833" txt_i="17797" txt_f="18149">Given the prevalence of CAM, the many various CAM therapies used for patients with FMS, and the cost associated with their use, it appears prudent that each of these therapies should be carefully assessed, initially with early phase trials. If the early phase trials result in promising findings, adequately powered clinical trials should be performed.</offsets></p><p><offsets xml_i="25840" xml_f="26089" txt_i="18150" txt_f="18399">The results of this randomized, double-blind, placebo-controlled, early phase trial of soy shakes for patients with FMS suggests that, on the basis of FIQ scores and CES-D scores, dietary soy supplementation is no more beneficial than casein shakes.</offsets></p></sec></body><back><ack><title>Acknowledgments</title><p>The authors acknowledge the study sponsor, Physicians Pharmaceuticals, Inc, Kernersville, North Carolina, for its support of this study.</p></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldenberg</surname><given-names>DL</given-names></name><name><surname>Burckhardt</surname><given-names>C</given-names></name><name><surname>Crofford</surname><given-names>L</given-names></name></person-group><article-title>Management of fibromyalgia syndrome</article-title><source><italic>Journal of the American Medical Association</italic></source><year>2004</year><volume>292</volume><issue>19</issue><fpage>2388</fpage><lpage>2395</lpage><pub-id pub-id-type="pmid">15547167</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolfe</surname><given-names>F</given-names></name><name><surname>Smythe</surname><given-names>HA</given-names></name><name><surname>Yunus</surname><given-names>MB</given-names></name><etal></etal></person-group><article-title>The American College of Rheumatology 1990. Criteria for the classification of fibromyalgia. Report of the Multicenter Criteria Committee</article-title><source><italic>Arthritis and Rheumatism</italic></source><year>1990</year><volume>33</volume><issue>2</issue><fpage>160</fpage><lpage>172</lpage><pub-id pub-id-type="pmid">2306288</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holdcraft</surname><given-names>LC</given-names></name><name><surname>Assefi</surname><given-names>N</given-names></name><name><surname>Buchwald</surname><given-names>D</given-names></name></person-group><article-title>Complementary and alternative medicine in fibromyalgia and related syndromes</article-title><source><italic>Best Practice and Research: Clinical Rheumatology</italic></source><year>2003</year><volume>17</volume><issue>4</issue><fpage>667</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">12849718</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>JK</given-names></name><name><surname>Mihaliak</surname><given-names>K</given-names></name><name><surname>Kroenke</surname><given-names>K</given-names></name><name><surname>Bradley</surname><given-names>J</given-names></name><name><surname>Tierney</surname><given-names>WM</given-names></name><name><surname>Weinberger</surname><given-names>M</given-names></name></person-group><article-title>Use of complementary therapies for arthritis among patients of rheumatologists</article-title><source><italic>Annals of Internal Medicine</italic></source><year>1999</year><volume>131</volume><issue>6</issue><fpage>409</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">10498556</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herman</surname><given-names>CJ</given-names></name><name><surname>Allen</surname><given-names>P</given-names></name><name><surname>Hunt</surname><given-names>WC</given-names></name><name><surname>Prasad</surname><given-names>A</given-names></name><name><surname>Brady</surname><given-names>TJ</given-names></name></person-group><article-title>Use of complementary therapies among primary care clinic patients with arthritis</article-title><source><italic>Preventing Chronic Disease</italic></source><year>2004</year><volume>1</volume><issue>4</issue><fpage>p. A12</fpage><pub-id pub-id-type="pmid">15670444</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahner-Roedler</surname><given-names>DL</given-names></name><name><surname>Elkin</surname><given-names>PL</given-names></name><name><surname>Vincent</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Use of complementary and alternative medical therapies by patients referred to a fibromyalgia treatment program at a Tertiary Care Center</article-title><source><italic>Mayo Clinic Proceedings</italic></source><year>2005</year><volume>80</volume><issue>1</issue><fpage>55</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">15667030</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ernst</surname><given-names>E</given-names></name></person-group><article-title>Musculoskeletal conditions and complementary/alternative medicine</article-title><source><italic>Best Practice and Research: Clinical Rheumatology</italic></source><year>2004</year><volume>18</volume><issue>4</issue><fpage>539</fpage><lpage>556</lpage><pub-id pub-id-type="pmid">15301985</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shir</surname><given-names>Y</given-names></name><name><surname>Raja</surname><given-names>SN</given-names></name><name><surname>Weissman</surname><given-names>CS</given-names></name><name><surname>Campbell</surname><given-names>JN</given-names></name><name><surname>Seltzer</surname><given-names>Z</given-names></name></person-group><article-title>Consumption of soy diet before nerve injury preempts the development of neuropathic pain in rats</article-title><source><italic>Anesthesiology</italic></source><year>2001</year><volume>95</volume><issue>5</issue><fpage>1238</fpage><lpage>1244</lpage><pub-id pub-id-type="pmid">11684996</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shir</surname><given-names>Y</given-names></name><name><surname>Sheth</surname><given-names>R</given-names></name><name><surname>Campbell</surname><given-names>JN</given-names></name><name><surname>Raja</surname><given-names>SN</given-names></name><name><surname>Seltzer</surname><given-names>Z</given-names></name></person-group><article-title>Soy-containing diet suppresses chronic neuropathic sensory disorders in rats</article-title><source><italic>Anesthesia and Analgesia</italic></source><year>2001</year><volume>92</volume><issue>4</issue><fpage>1029</fpage><lpage>1034</lpage><pub-id pub-id-type="pmid">11273945</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shir</surname><given-names>Y</given-names></name><name><surname>Campbell</surname><given-names>JN</given-names></name><name><surname>Raja</surname><given-names>SN</given-names></name><name><surname>Seltzer</surname><given-names>Z</given-names></name></person-group><article-title>The correlation between dietary soy phytoestrogens and neuropathic pain behavior in rats after partial denervation</article-title><source><italic>Anesthesia and Analgesia</italic></source><year>2002</year><volume>94</volume><issue>2</issue><fpage>421</fpage><lpage>426</lpage><pub-id pub-id-type="pmid">11812712</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pérez</surname><given-names>J</given-names></name><name><surname>Ware</surname><given-names>MA</given-names></name><name><surname>Chevalier</surname><given-names>S</given-names></name><name><surname>Gougeon</surname><given-names>R</given-names></name><name><surname>Bennett</surname><given-names>GJ</given-names></name><name><surname>Shir</surname><given-names>Y</given-names></name></person-group><article-title>Dietary fat and protein interact in suppressing neuropathic pain-related disorders following a partial sciatic ligation injury in rats</article-title><source><italic>Pain</italic></source><year>2004</year><volume>111</volume><issue>3</issue><fpage>297</fpage><lpage>305</lpage><pub-id pub-id-type="pmid">15363873</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arjmandi</surname><given-names>BH</given-names></name><name><surname>Khalil</surname><given-names>DA</given-names></name><name><surname>Lucas</surname><given-names>EA</given-names></name><etal></etal></person-group><article-title>Soy protein may alleviate osteoarthritis symptoms</article-title><source><italic>Phytomedicine</italic></source><year>2004</year><volume>11</volume><issue>7-8</issue><fpage>567</fpage><lpage>575</lpage><pub-id pub-id-type="pmid">15636169</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeiffer</surname><given-names>A</given-names></name><name><surname>Thompson</surname><given-names>JM</given-names></name><name><surname>Nelson</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Effects of a 1.5-day multidisciplinary outpatient treatment program for fibromyalgia: a pilot study</article-title><source><italic>American Journal of Physical Medicine and Rehabilitation</italic></source><year>2003</year><volume>82</volume><issue>3</issue><fpage>186</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">12595770</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burckhardt</surname><given-names>CS</given-names></name><name><surname>Clark</surname><given-names>SR</given-names></name><name><surname>Bennett</surname><given-names>RM</given-names></name></person-group><article-title>The fibromyalgia impact questionnaire: development and validation</article-title><source><italic>Journal of Rheumatology</italic></source><year>1991</year><volume>18</volume><issue>5</issue><fpage>728</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">1865419</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radloff</surname><given-names>LS</given-names></name></person-group><article-title>The CES-D Scale: a self-report depression scale for research in the general population</article-title><source><italic>Applied Psychological Measurement</italic></source><year>1977</year><volume>1</volume><fpage>385</fpage><lpage>401</lpage></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weissman</surname><given-names>MM</given-names></name><name><surname>Myers</surname><given-names>JK</given-names></name><name><surname>Harding</surname><given-names>PS</given-names></name></person-group><article-title>Psychiatric disorders in a U.S. urban community: 1975-1976</article-title><source><italic>American Journal of Psychiatry</italic></source><year>1978</year><volume>135</volume><issue>4</issue><fpage>459</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">637143</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turk</surname><given-names>DC</given-names></name><name><surname>Okifuji</surname><given-names>A</given-names></name><name><surname>Sinclair</surname><given-names>JD</given-names></name><name><surname>Starz</surname><given-names>TW</given-names></name></person-group><article-title>Interdisciplinary treatment for fibromyalgia syndrome: clinical and statistical significance</article-title><source><italic>Arthritis Care and Research</italic></source><year>1998</year><volume>11</volume><issue>3</issue><fpage>186</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">9782810</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aickin</surname><given-names>M</given-names></name></person-group><article-title>Separation tests for early-phase complementary and alternative medicine comparative trials</article-title><source><italic>Evidence-Based Integrative Medicine</italic></source><year>2004</year><volume>1</volume><issue>4</issue><fpage>225</fpage><lpage>232</lpage></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aickin</surname><given-names>M</given-names></name></person-group><article-title>The importance of early phase research</article-title><source><italic>Journal of Alternative and Complementary Medicine</italic></source><year>2007</year><volume>13</volume><issue>4</issue><fpage>447</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">17532739</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolfe</surname><given-names>F</given-names></name><name><surname>Anderson</surname><given-names>J</given-names></name><name><surname>Harkness</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Health status and disease severity in fibromyalgia: results of a six-center longitudinal study</article-title><source><italic>Arthritis and Rheumatism</italic></source><year>1997</year><volume>40</volume><issue>9</issue><fpage>1571</fpage><lpage>1579</lpage><pub-id pub-id-type="pmid">9324010</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haddad</surname><given-names>PS</given-names></name><name><surname>Azar</surname><given-names>GA</given-names></name><name><surname>Groom</surname><given-names>S</given-names></name><name><surname>Boivin</surname><given-names>M</given-names></name></person-group><article-title>Natural health products, modulation of immune function and prevention of chronic diseases</article-title><source><italic>Evidence-Based Complementary and Alternative Medicine</italic></source><year>2005</year><volume>2</volume><issue>4</issue><fpage>513</fpage><lpage>520</lpage><pub-id pub-id-type="pmid">16322809</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Flow chart of patients in the placebo-controlled soy supplement trial.</p></caption><graphic xlink:href="ECAM2011-350697.001"></graphic></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Total FIQ scores of patients in soy supplement trial, with intent-to-treat analysis (A–D) and per–protocol analysis (E–H). Score of patients randomly assigned to receive soy at study entry (A) and score of patients after 6 weeks of soy treatment (B). Score of patients randomly assigned to receive placebo at study entry (C) and score of patients after 6 weeks of placebo (D). Score of patients randomly assigned to receive soy at study entry (E) and score of patients after 6 weeks of soy treatment (F). Score of patients randomly assigned to receive placebo at study entry (G) and score of patients after 6 weeks of placebo (H).</p></caption><graphic xlink:href="ECAM2011-350697.002"></graphic></fig><fig id="fig3" position="float"><label>Figure 3</label><caption><p>CES-D scores of patients in soy supplement trial, with intent-to-treat analysis (A–D) and per-protocol analysis (E–H). Score of patients randomly assigned to receive soy at study entry (A) and score of patients after 6 weeks of soy treatment (B). Score of patients randomly assigned to receive placebo at study entry (C) and score of patients after 6 weeks of placebo (D). Score of patients randomly assigned to receive soy at study entry (E) and score of patients after 6 weeks of soy treatment (F). Score of patients randomly assigned to receive placebo at study entry (G) and score of patients after 6 weeks of placebo (H).</p></caption><graphic xlink:href="ECAM2011-350697.003"></graphic></fig><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Summary of data analysis with a separation test <sup>a</sup>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Outcome</th><th align="center" colspan="2" rowspan="1">Control (placebo)</th><th align="center" colspan="2" rowspan="1">Treatment (soy)</th><th align="left" rowspan="2" colspan="1">SDE</th><th align="left" rowspan="2" colspan="1">Δ/2 <sup>b</sup>
</th><th align="left" rowspan="2" colspan="1">Mean difference (placebo/soy)</th><th align="left" rowspan="2" colspan="1">Separation in favor of placebo or soy <sup>c</sup>
</th><th align="left" rowspan="2" colspan="1">Further research with soy indicated?</th></tr><tr><th align="left" rowspan="1" colspan="1"></th><th rowspan="1" colspan="1">Mean change in scores</th><th align="left" rowspan="1" colspan="1">95% CI</th><th align="left" rowspan="1" colspan="1">Mean change in scores</th><th align="left" rowspan="1" colspan="1">95% CI</th></tr></thead><tbody><tr><td align="center" colspan="10" rowspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">Intent-to-treat analysis</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">F1-11<sup>d</sup>
</td><td align="left" rowspan="1" colspan="1">−0.51</td><td align="left" rowspan="1" colspan="1">−3.55 to 2.54</td><td align="left" rowspan="1" colspan="1">−0.07</td><td align="left" rowspan="1" colspan="1">−1.93 to 1.79</td><td align="left" rowspan="1" colspan="1">0.18</td><td align="left" rowspan="1" colspan="1">0.15</td><td align="left" rowspan="1" colspan="1">−0.44</td><td align="left" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">F12<sup>d</sup>
</td><td align="left" rowspan="1" colspan="1">−2.06</td><td align="left" rowspan="1" colspan="1">−8.69 to 4.57</td><td align="left" rowspan="1" colspan="1">−1.26</td><td align="left" rowspan="1" colspan="1">−7.00 to 4.48</td><td align="left" rowspan="1" colspan="1">0.45</td><td align="left" rowspan="1" colspan="1">0.37</td><td align="left" rowspan="1" colspan="1">−0.80</td><td align="left" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">F13<sup>d</sup>
</td><td align="left" rowspan="1" colspan="1">−1.12</td><td align="left" rowspan="1" colspan="1">−7.01 to 4.77</td><td align="left" rowspan="1" colspan="1">−0.32</td><td align="left" rowspan="1" colspan="1">−5.08 to 4.44</td><td align="left" rowspan="1" colspan="1">0.39</td><td align="left" rowspan="1" colspan="1">0.32</td><td align="left" rowspan="1" colspan="1">−0.80</td><td align="left" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">F14-20<sup>d</sup>
</td><td align="left" rowspan="1" colspan="1">−8.84</td><td align="left" rowspan="1" colspan="1">−38.73 to 21.05</td><td align="left" rowspan="1" colspan="1">−6.56</td><td align="left" rowspan="1" colspan="1">−29.36 to 16.24</td><td align="left" rowspan="1" colspan="1">1.91</td><td align="left" rowspan="1" colspan="1">1.57</td><td align="left" rowspan="1" colspan="1">−2.28</td><td align="left" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">Total FIQ scores</td><td align="left" rowspan="1" colspan="1">−12.52</td><td align="left" rowspan="1" colspan="1">−53.34 to 28.29</td><td align="left" rowspan="1" colspan="1">−8.21</td><td align="left" rowspan="1" colspan="1">−39.39 to 22.97</td><td align="left" rowspan="1" colspan="1">2.61</td><td align="left" rowspan="1" colspan="1">2.15</td><td align="left" rowspan="1" colspan="1">−4.32</td><td align="left" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">Total CES-D scores</td><td align="left" rowspan="1" colspan="1">−5.12</td><td align="left" rowspan="1" colspan="1">−31.60 to 21.36</td><td align="left" rowspan="1" colspan="1">−1.92</td><td align="left" rowspan="1" colspan="1">−8.12 to 4.28</td><td align="left" rowspan="1" colspan="1">1.39</td><td align="left" rowspan="1" colspan="1">1.15</td><td align="left" rowspan="1" colspan="1">−3.20</td><td align="left" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">No</td></tr><tr><td align="center" colspan="10" rowspan="1">
<hr></hr>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Per-protocol analysis</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td><td align="left" rowspan="1" colspan="1">
</td></tr><tr><td align="left" rowspan="1" colspan="1">F1-11<sup>d</sup>
</td><td align="left" rowspan="1" colspan="1">−0.79</td><td align="left" rowspan="1" colspan="1">−4.52 to 2.94</td><td align="left" rowspan="1" colspan="1">−0.15</td><td align="left" rowspan="1" colspan="1">−2.89 to 2.59</td><td align="left" rowspan="1" colspan="1">0.32</td><td align="left" rowspan="1" colspan="1">0.27</td><td align="left" rowspan="1" colspan="1">−0.64</td><td align="left" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">F12<sup>d</sup>
</td><td align="left" rowspan="1" colspan="1">−3.22</td><td align="left" rowspan="1" colspan="1">−10.63 to 4.20</td><td align="left" rowspan="1" colspan="1">−2.62</td><td align="left" rowspan="1" colspan="1">−10.16 to 4.92</td><td align="left" rowspan="1" colspan="1">0.71</td><td align="left" rowspan="1" colspan="1">0.58</td><td align="left" rowspan="1" colspan="1">−0.60</td><td align="left" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">F13<sup>d</sup>
</td><td align="left" rowspan="1" colspan="1">−1.75</td><td align="left" rowspan="1" colspan="1">−8.89 to 5.39</td><td align="left" rowspan="1" colspan="1">−0.67</td><td align="left" rowspan="1" colspan="1">−7.63 to 6.29</td><td align="left" rowspan="1" colspan="1">0.68</td><td align="left" rowspan="1" colspan="1">0.56</td><td align="left" rowspan="1" colspan="1">−1.08</td><td align="left" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">No</td></tr><tr><td align="left" rowspan="1" colspan="1">F14-20<sup>d</sup>
</td><td align="left" rowspan="1" colspan="1">−13.81</td><td align="left" rowspan="1" colspan="1">−47.69 to 20.07</td><td align="left" rowspan="1" colspan="1">−13.67</td><td align="left" rowspan="1" colspan="1">−40.64 to 13.30</td><td align="left" rowspan="1" colspan="1">2.95</td><td align="left" rowspan="1" colspan="1">2.42</td><td align="left" rowspan="1" colspan="1">−0.15</td><td align="left" rowspan="1" colspan="1">Neither</td><td align="left" rowspan="1" colspan="1">…<sup>e</sup>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Total FIQ scores</td><td align="left" rowspan="1" colspan="1">−19.57</td><td align="left" rowspan="1" colspan="1">−65.40 to 26.26</td><td align="left" rowspan="1" colspan="1">−17.10</td><td align="left" rowspan="1" colspan="1">−55.62 to 21.42</td><td align="left" rowspan="1" colspan="1">4.06</td><td align="left" rowspan="1" colspan="1">3.34</td><td align="left" rowspan="1" colspan="1">−2.47</td><td align="left" rowspan="1" colspan="1">Neither</td><td align="left" rowspan="1" colspan="1">…</td></tr><tr><td align="left" rowspan="1" colspan="1">Total CES-D scores</td><td align="left" rowspan="1" colspan="1">−8.00</td><td align="left" rowspan="1" colspan="1">−40.05 to 24.05</td><td align="left" rowspan="1" colspan="1">−4.00</td><td align="left" rowspan="1" colspan="1">−10.99 to 2.99</td><td align="left" rowspan="1" colspan="1">2.37</td><td align="left" rowspan="1" colspan="1">1.95</td><td align="left" rowspan="1" colspan="1">−4.00</td><td align="left" rowspan="1" colspan="1">Placebo</td><td align="left" rowspan="1" colspan="1">No</td></tr></tbody></table><table-wrap-foot><fn><p> 
<sup>a</sup>As described by Aickin [<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>];  <sup>b</sup>Δ/2 = 1.645∗SDE/2;  <sup>c</sup>If the mean difference exceeds Δ/2 (in the favorable direction, positive for soy), further research is recommended;  <sup>d</sup>F1-11, questions 1-11 of FIQ, which rate the ability to complete various activities and are scored and summed to yield 1 physical impairment score (0, no impairment; 10, maximum impairment); F12, question 12 of FIQ, which inquires about the number of days out of the past 7 days when the patient felt well (0, no impairment; 10, maximum impairment); F13, question 13 of FIQ, which inquires about the number of days during the past week when the patient missed work, including housework, because of fibromyalgia (0, no impairment; 10, maximum impairment); F14-20, questions 14-20 of FIQ, which are a series of visual analog scales for rating the various symptoms characteristic of FMS (0, no impairment; 70, maximum impairment);  <sup>e</sup>Ellipses indicate not enough information to make a recommendation. CI, confidence interval.</p></fn></table-wrap-foot></table-wrap></floats-group></article>